{"entity":{"id":"nct07392736","kind":"trial","name":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","aka":[],"tldr":"A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Advenchen Laboratories, LLC, now recruiting.","summary":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT07392736 by Advenchen Laboratories, LLC, with 228 participants planned, started 2021-10-26 and due to reach its primary completion in 2029-11-07. Interventions recorded: AL8326 tablets and Toripalimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07392736","url":"https://clinicaltrials.gov/study/NCT07392736"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab"],"companies":["advenchen-laboratories"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07392736","phase":"1/2","setting":"A Phase I/IIa Clinical Trial of AL8326 Tablets Combined With Toripalimab in the Treatment of Advanced Recurrent or Metastatic Solid Tumors","sponsor":"Advenchen Laboratories, LLC","started":"2021-10-26","startedType":"actual","enrolled":228,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07392736/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"advenchen-laboratories","kind":"company","name":"Advenchen Laboratories","route":"/companies/advenchen-laboratories/"}]}}